Genentech's $379M retention plan

31 August 2008

California, USA-based firm Genentech is to pay its employees $371.0 million in bonuses to retain their services in advance of a possible takeover by Swiss drug major Roche.

The company says it will offer the retention plan to virtually all of its 10,700 employees, and chief executive Arthur Levinson will be offered $8.7 million.

The bonuses replace 2008 stock option grants. The firm says the payments will cost around $0.22 per share over three years, whereas the stock options would have cost $0.23 per share over six years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >




Today's issue

Company Spotlight